suizenji + folinic acid + fluorouracil + irinotecan + oxaliplatin

A multi-agent combination therapy composed of **suizenji** (nature and role unclear in the context of oncology), **folinic acid** (leucovorin), **fluorouracil** (5-FU), **irinotecan**, and **oxaliplatin**. Folinic acid, fluorouracil, irinotecan, and oxaliplatin are established agents used in regimens such as FOLFOXIRI for the treatment of advanced or metastatic colorectal cancer. Folinic acid enhances the cytotoxic effect of fluorouracil by stabilizing the bond between 5-FU’s active metabolite and the target enzyme; fluorouracil is a pyrimidine analog inhibiting DNA synthesis; irinotecan is a topoisomerase I inhibitor causing DNA damage during replication; oxaliplatin is a platinum-based DNA crosslinking agent. The mechanism of action and contribution of the component "suizenji" is not established from current oncology or pharmacological sources, and no evidence of its use in standard chemotherapeutic protocols is available[2][4][9]. This combination would be anticipated to exert antitumor effects via **multiple complementary cytotoxic mechanisms** against rapidly dividing cancer cells.